Sativex Satisfies Regulatory Hurdle, UK

The makers of cannabis-based treatment Sativex have today reported the results of a trial held to establish how effective the therapy is in people with multiple sclerosis (MS). GW Pharmaceuticals were asked by the Medicines and Healthcare Regulatory Authority (MHRA) to hold the withdrawal study, which evaluated 36 people with spasticity and who had previously been taking Sativex on prescription.

More: continued here

Filed under: Multiple Sclerosis on February 25th, 2009